Literature DB >> 19879656

Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.

Parvathi Ranganathan1, Hao Chen, Miranda K Adelman, Samuel F Schluter.   

Abstract

In this report, we show that affinity purified human anti-delta opioid receptor (DOR) autoantibodies from IVIG are specific to DOR and possess agonistic properties displayed by their ability to dramatically decrease forskolin stimulated cAMP accumulation. Anti-DOR autoantibody also caused phosphorylation of the opioid receptor. Anti-DOR autoantibody treatment showed a significant reduction in CXCR4 gene expression as well as surface protein expression. In contrast, anti-DOR autoantibody treatment significantly upregulated CCR5 gene and protein expression. The presence of anti-DOR autoantibodies in IVIG and their potent immunomodulatory activity is further evidence to support the cross-talk between the neuroendocrine and immune systems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879656      PMCID: PMC2861486          DOI: 10.1016/j.jneuroim.2009.10.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  80 in total

1.  A comparative study of immunomodulation produced by in vitro exposure to delta opioid receptor agonist peptides.

Authors:  R V House; P T Thomas; H N Bhargava
Journal:  Peptides       Date:  1996       Impact factor: 3.750

Review 2.  Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action.

Authors:  R D Mellon; B M Bayer
Journal:  J Neuroimmunol       Date:  1998-03-15       Impact factor: 3.478

Review 3.  Evidence for opioid receptors on cells involved in host defense and the immune system.

Authors:  B M Sharp; S Roy; J M Bidlack
Journal:  J Neuroimmunol       Date:  1998-03-15       Impact factor: 3.478

Review 4.  The opioid-cytokine connection.

Authors:  P K Peterson; T W Molitor; C C Chao
Journal:  J Neuroimmunol       Date:  1998-03-15       Impact factor: 3.478

5.  Implication of the first and third extracellular loops of the mu-opioid receptor in the formation of the ligand binding site: a study using chimeric mu-opioid/angiotensin receptors.

Authors:  G Dietrich; G Gaibelet; R Capeyrou; J L Butour; F Pontet; L J Emorine
Journal:  J Neurochem       Date:  1998-05       Impact factor: 5.372

6.  delta opioid receptor expression is induced by concanavalin A in CD4+ T cells.

Authors:  B Miller
Journal:  J Immunol       Date:  1996-12-15       Impact factor: 5.422

7.  The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.

Authors:  E V Varga; X Li; D Stropova; T Zalewska; R S Landsman; R J Knapp; E Malatynska; K Kawai; A Mizusura; H Nagase; S N Calderon; K Rice; V J Hruby; W R Roeske; H I Yamamura
Journal:  Mol Pharmacol       Date:  1996-12       Impact factor: 4.436

8.  Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations.

Authors:  M Svenson; M B Hansen; C Ross; M Diamant; K Rieneck; H Nielsen; K Bendtzen
Journal:  Blood       Date:  1998-03-15       Impact factor: 22.113

9.  Signaling through delta opioid receptors on murine splenic T cells and stably transfected Jurkat cells.

Authors:  B M Sharp; D J McKean; K McAllen; N A Shahabi
Journal:  Ann N Y Acad Sci       Date:  1998-05-01       Impact factor: 5.691

10.  Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization.

Authors:  M C Grimm; A Ben-Baruch; D D Taub; O M Howard; J H Resau; J M Wang; H Ali; R Richardson; R Snyderman; J J Oppenheim
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  4 in total

Review 1.  Autoantibodies as Endogenous Modulators of GPCR Signaling.

Authors:  Meredith A Skiba; Andrew C Kruse
Journal:  Trends Pharmacol Sci       Date:  2020-12-24       Impact factor: 14.819

Review 2.  Recent advances on the δ opioid receptor: from trafficking to function.

Authors:  Louis Gendron; Nitish Mittal; Hélène Beaudry; Wendy Walwyn
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 3.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

4.  T Cells as an Emerging Target for Chronic Pain Therapy.

Authors:  Geoffroy Laumet; Jiacheng Ma; Alfred J Robison; Susmita Kumari; Cobi J Heijnen; Annemieke Kavelaars
Journal:  Front Mol Neurosci       Date:  2019-09-11       Impact factor: 5.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.